372198-69-1

Basic information

• Product Name: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester
• Synonyms: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester;ethyl 6-broMoH-iMidazo[1,2-a]pyridine-3-carboxylate;6-Bromoimidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester;6-bromoImidazo[1,2-a]pyridine-3-Carbocylic acid ethyl ester;Midazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester
• CAS NO: 372198-69-1
• Molecular Formula: C₁₀H₉BrN₂O₂
• Molecular Weight: 269.09466
• Product Categories: Heterocycle-Pyridine series
• Mol File: 372198-69-1.mol

Chemical Properties

• Appearance: /
• Density: 1.60
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.29±0.50(Predicted)
• CAS DataBase Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester(372198-69-1)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-broMo-, ethyl ester(372198-69-1)

Safety Data

• Hazardous Substances Data: 372198-69-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-bromo-, ethyl ester is used as a building block for the synthesis of bioactive compounds for the treatment of conditions such as cancer, inflammation, and neurological disorders. Its unique structure and properties contribute to the development of novel therapeutic agents with potential applications in these areas.
Used in Material Science:
Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-bromo-, ethyl ester is also investigated for its potential application in the field of material science. It has been studied for its use in the development of organic semiconductors and optoelectronic devices, where its chemical properties and stability can be leveraged to improve the performance of these technologies.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 
• 105-36-2 ethyl bromoacetate 
• 33142-21-1 ethyl 2-chloro-3-oxopropanoate 
• 105-39-5 chloroacetic acid ethyl ester 
• 109-94-4 formic acid ethyl ester 
• 474706-74-6 6-bromo-3-iodoimidazo[1,2-a]pyridine 
• 541-41-3 chloroformic acid ethyl ester 
• 1004550-24-6 ethyl 2-chloro-3-oxopropanoate potassium salt 
• 913287-11-3 2-chloro-3-oxopropanoate potassium salt 

Downstream Products

• 1276110-06-5 ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]-pyridine-3-carboxylate 
• 1426133-22-3 methyl 3-(3-(3-(6-(3-cyanopropyl)imidazo[1,2-a]pyridine-3-carboxamido)-4-methylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426133-27-8 methyl 3-(3-(3-(6-(2-cyanoethyl)imidazo[1,2-a]pyridine-3-carboxamido)-4-methylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426133-28-9 methyl 3-(3-(4-methyl-3-(6-(3-oxobutyl)imidazo[1,2-a]pyridine-3-carboxamido)phenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426133-30-3 methyl 3-(3-(3-(6-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridine-3-carboxamido)-4-methylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426448-44-3 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-oxobutyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-45-4 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-(3-hydroxy-3-methylbutyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426448-54-5 N-{5-[5-(3,3-difluorocyclobutyl)-1,2,4-oxadiazol-3-yl]-2-methylphenyl}-6-[2-(4-methylpiperazin-1-yl)ethyl]imidazo[1,2-a]pyridine-3-carboxamide 
• 1432912-80-5 6-bromo-N-(2,4-dimethoxybenzyl)imidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors

Inhibition of cdc2-like kinase1 (CLK1) could efficiently induce autophagy and it has been thought as a potential target for treatment of autophagy-related diseases. Herein we report the discovery of a series of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors. Among them, compound 9e is the most potent one, which exhibits an IC50 value of 4 nM against CLK1 kinase. In vitro, this compound reduces the phosphorylation level of the typical downstream substrates of CLK1 and affects their subcellular redistribution. Further study indicates that 9e is efficient to induce autophagy. Overall, this study provides a promising lead compound for drug discovery targeting CLK1 kinase.

Preparation and application of imidazo aromatic ring compounds

The invention provides preparation and application of imidazo aromatic ring compounds, and particularly provides compounds as shown in the following formula I. The definition of each group is as shownin the specification. The compounds have TRK kinase inh

Design, Synthesis, and Biological Evaluation of Imidazo[1,2- a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.

Aromatic heterocyclic compound serving as PI3K/mTOR kinase regulator and preparation method and application of aromatic heterocyclic compound

The invention discloses 6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-a]pyridines shown as a formula (I) or 6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-b]pyridazine derivatives or pharmaceutically acceptable salts thereof and a preparation method. The invention also discloses application of 6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-a]pyridines or6-(6-substituted group-5-sulfonamido-3-pyridinyl)imidazo[1,2-b]pyridazine derivatives or pharmaceutically acceptable salts thereof to preparation of medicines for resisting tumors, treating cerebral ischemia and treating diabetes mellitus as a PI3K/mTOR inhibitor.

Convenient two-step one-pot synthesis of 3-substituted imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines

Abstract: A convenient and novel two-step one-pot method for the synthesis of 3-substituted imidazo[1,2-a]pyridines and 3-substituted imidazo[1,2-b]pyridazines was developed through the reaction of heterocyclic amines and N,?N-dimethylformamide dimethyl a

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS

This disclosure relates, inter alia, to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.